Pacer Funds Pacer Pacific Asset Floating Rate High Income ETF (ARCA: FLRT)

Latest news for Pacer Funds Pacer Pacific Asset Floating Rate High Income ETF (ARCA:FLRT)

Pacer Funds Pacer Pacific Asset Floating Rate High Income ETF

AdvisorShares Pacific Asset Enhanced Floating Rate ETF

Pacific Asset Management LLC (the Sub-Adviser) seeks to achieve the Funds investment objective by selecting a focused portfolio comprised primarily of income-producing adjustable rate securities.

Pacer Pacific Asset Floating Rate High Income ETF

Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved patient outcomes
Favorable early safety, efficacy, tolerability and durability of remission data informed Aptevo's ongoing RAINIER Phase 1b/2 trial

Biotech

News

General

APVO

Aptevo Therapeutics Reports First Patient Dosed In Ongoing RAINIER Trial Saw 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment

WIIM

HOTH

Hoth Therapeutics shares are trading higher after the company announced its board has approved the purchase of up to $1 million in Bitcoin.

<ul>
<li>Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region</li>
<li>Genting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products &nbsp;</li>
<li>Strategic partnership positions Celularity to be a key supplier of innovative stem cell and regenerative medicine products for use in the Asia Pacific region &nbsp;</li>
</ul>
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity"), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad's&nbsp;<a href="https://www.globenewswire.com/Tracker?data=AvMRVVJll3lEBOW7REb68c3z5rtvvchzq1JOh8QpUmFD9re2jVYzy8U-8UNxpIQXOBpk4MgAT8saMPDa7IcNkIrfUCWEAAX--zkMWR9AajKrd4wzvncLV7TG6MrLslu-7rIYLmhsJ7Cl8IXtyNeYn3-Hhaf9WYtr7WzdQnSypCN35DQjJGnueTt0sWbmdpK5uo8Xat0MgEH9HDt0a1SSUhKJqUEP0q5C_yQzZ8PW2fwmf6AQxUvschIta0d32TkE">press release</a>. The new center is expected to commence commercial operations towards the end of 2026.

Global

CELU

Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific

Benchmark analyst Matthew Harrigan reiterates Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

CMCSA

Benchmark Reiterates Buy on Comcast, Maintains $60 Price Target

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

PODD

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

PAVM

PAVmed shares are trading higher after the company announced it and Lucid Diagnostics submitted complete clinical evidence for its Esoguard esophageal DNA test.

NMHI

Nature's Miracle Converts $2M Debt To Equity At $0.088 Per Share, With CEO James Li Converting $577K In Personal Loans And President Jonathan Zhang Converting Trade Payables To Uninet Inc.

Earnings

REBN

Reborn Coffee Q3 EPS $(1.40) Up From $(1.82) YoY; Revenue $1.3M Down From $1.5M YoY

In the quiet hum of a manufacturing facility in Chico, California, lies a story as old as the American dream. It's about a man who turned adversity into opportunity, using grit, ingenuity and a commitment to better his community. From the fields to the factory floor, it's a reminder of the enduring belief that work is not just about profit, it's about purpose and building something that lasts while and uplifting others along the way.
At the heart of this story is Dave Peterson, a former Green Beret and military psychologist, who found his calling in cannabis. After years of serving his country and battling PTSD, Peterson built a business that combines cutting-edge automation with a mission to educate and empower the next generation. His <a href="https://chicocannabiscompany.com/">Chico California Cannabis Company (C4) </a>isn't just about making products, it's about making progress.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Rediscovering Purpose: A Revelation That Sparked A Journey</h3>
After serving multiple tours in Afghanistan and Kosovo, Peterson faced the challenges of reintegration and PTSD. Disheartened by traditional treatments that emphasized pharmaceuticals, he turned to gardening with cannabis, initially as a suggestion from friends in the industry. What began as an experiment became life-changing.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1019" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12-1019x1024.jpg" alt="" class="wp-image-656053" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12-1019x1024.jpg 1019w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12-300x300.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12-150x150.jpg 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12-768x772.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175632/XYLEM_C4_-12.jpg 1075w" sizes="(max-width: 1019px) 100vw, 1019px" /><figcaption class="wp-element-caption">Dave Peterson in Chico, California. </figcaption></figure>
&#8220;I was out in the sun, grounded to the earth, and working with these plants. Slowly, my symptoms began to subside—better sleep, less hypersensitivity to noise, and improved overall health,&#8221; Peterson told Benzinga Cannabis in an exclusive interview. The experience inspired him to transition from military service to the cannabis industry, seeing firsthand the plant's medicinal benefits.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41828889/exclusive-surviving-chavezs-venezuela-to-cbd-crash-ceo-reveals-how-to-profit-in-a-market-stuck-o">EXCLUSIVE: From Surviving Chavez&#8217;s Venezuela To The CBD Crash &#8211; CEO Reveals How To Profit In A Market Stuck On Repeat</a>
<h3 class="wp-block-heading">Automate And Conquer</h3>
Dave Peterson's military background, rooted in precision and strategic planning, provided him with a unique lens through which to view the cannabis industry. Early in his journey, he recognized a crucial shift: the cannabis market was evolving from small-scale craft operations to a competitive global industry where <a href="https://www.benzinga.com/general/biotech/24/10/41554695/exclusive-why-good-weed-and-good-friends-wont-cut-it-any-more-cannabis-industry-embraces-ai-autom">efficiency and scalability</a> were paramount.
&#8220;Looking at market trends and licensing data, it was clear that <a href="https://www.benzinga.com/general/biotech/24/08/40298228/think-you-can-do-it-all-20-000-reasons-why-automation-outperforms-a-broad-approach-in-cannabis">automation was the only way to cut costs</a> and keep production efficient,&#8221; Peterson said. Armed with data, he identified the inefficiencies that plagued traditional cannabis operations—manual processes, high overhead, and limited scalability.
Peterson's solution? Automation. His facility features state-of-the-art equipment such as the Xylem 3 cartridge filler and the APEHEX pre-roll machine. These machines, built by innovators who understand the nuances of cannabis processing, are helping operators like Peterson transform how the industry works.
After witnessing early adopters in the industry fail with repurposed equipment that wasn't fit for cannabis, Peterson waited until the technology matured. &#8220;In 2020 and 2021, we saw equipment that was finally functional, tailored for the unique needs of cannabis and hemp.&#8221; This strategic patience paid off: his initial automation investments yielded a return within just seven months, far exceeding the 18-month timeline he had planned for.
&#8220;Automation allowed us to scale up or down without the heavy burden of overhead, which is critical in this unpredictable market,&#8221; Peterson explained. By <a href="https://www.benzinga.com/general/biotech/23/08/33579692/cannabis-robots-meet-the-company-boosting-efficiency-and-margins-through-packaging-automation">automating labor-intensive tasks </a>like filling cartridges and rolling prerolls, his operation cut costs and improved turnaround times for clients.
Even more importantly, automation has enabled Peterson to thrive in a market with razor-thin margins, allowing C4 to undercut larger competitors weighed down by inefficient processes. &#8220;The industry is chaotic and unpredictable,&#8221; he noted. &#8220;We knew that by keeping our costs low and production reliable, we could survive—and even grow—in this environment.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41993054/was-the-whole-gummy-too-much-azuca-solves-the-cannabis-edibles-problem-with-food-tech">Was The Whole Gummy Too Much? Azuca Solves The Cannabis Edibles Problem With Food-Tech</a>
<h3 class="wp-block-heading">White-Label Partnerships: Smart Business </h3>
C4's business is built on collaboration, with a primary focus on<a href="https://www.benzinga.com/general/biotech/22/02/25149582/cannabis-supply-chain-lessons-learned-in-california"> white-label manufacturing</a>. Peterson has positioned the company as a solutions provider for a wide range of clients, from boutique cannabis brands to major cultivators. &#8220;We work with everyone—from small brands looking for turnkey solutions to major farms.&#8221; 
By offering custom agreements such as profit-sharing deals, the company ensures its partners can access high-quality products without the capital investment required to build their infrastructure.
Peterson&#8217;s relationships with top growers across California also play a critical role. He can secure premium cannabis biomass for his facility, which is then transformed into <a href="https://www.benzinga.com/topic/retail-cannabis">retail-ready products</a>. These products include cartridges, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">prerolls</a>, and extracts, all produced with cutting-edge equipment.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04-1024x683.jpg" alt="" class="wp-image-656058" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19175756/XYLEM_C4_-04.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Extraction Equipment -Courtesy of C4. </figcaption></figure>
C4's model is also about creating <a href="https://www.benzinga.com/topic/cannabis-branding">opportunities for brands</a>. &#8220;Some of our clients are just brands—they don't grow or manufacture at all. We handle everything from production to packaging, and they focus on sales and marketing.&#8221; 
This approach has made C4 indispensable for cash-strapped operators, as Peterson structures deal to accommodate limited resources through output splitting and flexible payment terms.
&#8220;Our goal was to create accessible, good products,&#8221; Peterson noted. By combining top-quality inputs with efficient automation, C4 delivers competitive pricing while maintaining strong profit margins.&nbsp;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41831831/no-middleman-no-markup-how-red-mesa-is-slashing-costs-with-around-the-clock-hemp-refinement">No Middleman, No Markup: How Red Mesa Is Slashing Costs With Around-The-Clock Hemp Refinement</a>
<h3 class="wp-block-heading">Pathways To Economic Mobility</h3>
For Peterson, the benefits of automation go beyond efficiency as they create opportunities for community development. Through C4, he trains young adults to operate and maintain <a href="https://www.benzinga.com/markets/cannabis/23/10/35071235/custom-automation-redefining-cannabis-pre-rolls-roi-the-rollpros-advantage">specialized equipment</a>, equipping them with skills applicable across industries.
&#8220;These machines aren't just about cannabis. The extraction and <a href="https://www.benzinga.com/general/social-media/24/11/42074616/expert-tips-to-create-effective-cannabis-content-on-instagram-tiktok-and-more-focus-on-the-content-not-the-packaging">packaging techniques</a> we use overlap with pharmaceuticals and essential oils,&#8221; Peterson said. &#8220;We're giving kids who lack direction a chance to learn a trade, earn a living, and build a future.&#8221;
This focus on workforce development echoes the history of American manufacturing, where trades provided pathways to economic mobility. Peterson sees this as a way to revive the spirit of technical education and localized production, which he contends has eroded over time.
<h3 class="wp-block-heading">Cannabis Machines: U.S. Made For Export</h3>
Peterson's business philosophy reflects the intersection of technological innovation and a belief in the cannabis plant's transformative potential. He sees cannabis not only as a medicinal product but also as a cornerstone of an industry capable of reshaping the American economy and conquering global cannabis markets overseas.&nbsp;
&#8220;Automation isn't just about making things faster, it's about creating sustainable systems and empowering people. Putting cannabis first is putting America first,&#8221; he told Benzinga, underscoring the potential for U.S.-made cannabis equipment to dominate global markets.
Read Next:<a href="https://www.benzinga.com/general/biotech/24/11/41997354/selling-weed-is-like-a-sneaker-drop-running-out-isnt-a-problem-for-this-company"> Selling Weed Is Like A Sneaker Drop: Running Out Isn&#8217;t A Problem For This Company</a>

Cannabis

Macro Economic Events

Entrepreneurship

Contracts

Retail Sales

Economics

Success Stories

Startups

Small Business

Exclusives

Tech

Interview

Cannabis Robots And The Search For Good Jobs: A Veteran's Mission To Keep The US Ahead In The Tech Race

EEIQ Estimates that the New Agreement has the Potential to Increase its&nbsp;International Student Enrollment by at Least 20%
MIDDLETOWN, Ohio, Nov. 20, 2024 /PRNewswire/ --&nbsp;EpicQuest Education Group International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>), ("EpicQuest Education", "EEIQ" or the "Company"), a provider of higher education for domestic and international students in the US, Canada and the UK, &nbsp;today announced that Davis University recently entered into a Transfer Articulation Agreement (the "Agreement") with The Center of Advanced Studies, based in Tokyo, Japan, that operates international study programs in numerous schools in Southeast Asia and South America. The Agreement, effective December 1, 2024, establishes a pathway for international students from five Southeast Asian and South American colleges and universities to complete associate and bachelor's degrees in business at Davis University.

EEIQ

EpicQuest Education Announces Agreement That Substantially Expands Its International Student Engagement From The Southeast Asian And South American Markets; Estimates That The New Agreement Has The Potential To Increase Its International Student Enrollment By At Least 20%

Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) reported better-than-expected fourth-<a href="https://www.benzinga.com/24/11/42083215/why-keysight-technologies-shares-are-trading-higher-by-over-9-here-are-20-stocks-moving-premarket">quarter financial results</a>.
Keysight Techs reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.57. The company reported quarterly sales of $1.287 billion which beat the analyst consensus estimate of $1.258 billion.
"Keysight executed well and delivered fourth-quarter revenue and earnings per share above the high end of guidance under market conditions which remained consistent with our expectations,&#8221; said Satish Dhanasekaran, president and CEO of Keysight. &#8220;As we look ahead, the strength of our differentiated portfolio, deep engagement with customers and the accelerating pace of technology innovation give us confidence in our ability to outperform as markets recover.&#8221;
Keysight expects first-quarter revenue to be in the range of $1.265 billion to $1.285 billion. The company expects first-quarter adjusted earnings to be between $1.65 and $1.71 per share
Keysight shares gained 0.5% to close at $152.13 on Tuesday.
These analysts made changes to their price targets on Keysight following earnings announcement.
<ul>
<li>Baird analyst Richard Eastman maintained Keysight with an Outperform and raised the price target from $163 to $180.</li>
<li>Deutsche Bank analyst Matthew Niknam maintained the stock with a Buy and raised the price target from $175 to $180.</li>
<li>Morgan Stanley analyst Meta Marshall maintained Keysight with an Overweight and raised the price target from $165 to $180.</li>
<li>Barclays analyst Tim Long maintained Keysight with an Overweight and raised the price target from $180 to $200.</li>
</ul>
Considering buying KEYS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20083618/image-209-1024x542.png" alt="" class="wp-image-656917" style="width:687px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20083618/image-209-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20083618/image-209-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20083618/image-209-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20083618/image-209.png 1222w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42086207/jim-cramer-likes-devon-energy-but-says-this-energy-stock-is-far-superior-to-devon">Jim Cramer Likes Devon Energy, But Calls Another Stock &#8216;Far Superior&#8217;</a></li>
</ul>

Markets

Trading Ideas

KEYS

These Analysts Boost Their Forecasts On Keysight Technologies Following Better-Than-Expected Earnings

Benchmark analyst Fawne Jiang reiterates Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with a Hold.

VIPS

Benchmark Reiterates Hold on Vipshop Holdings

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.
GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic&nbsp;plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen&#x2122; app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera&#x2122; continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen&#x2122; smart insulin pen with its newest Simplera&#x2122; CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.
With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection (MDI) therapy.&nbsp;

Medtronic Receives FDA Clearance For New InPen App, Paving The Way For Its Smart MDI System Launch With Simplera CGM

PRFX

PainReform Reports Partial Topline Data For PRF-110 Phase 3 Clinical Trial; Data Pertaining To Subsequent 24-Hpur Period Needed For Assessing Primary Endpoint Is Currently Unclear Due To Incoherence Of Data

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) inked a non-binding MOU for a multiyear agreement with LG Chem, a chemical company with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42083477/lg-chem-and-exxonmobil-sign-mou-for-lithium-offtake" rel="noreferrer noopener">diversified business portfolio</a>.
According to this, ExxonMobil will supply up to 100,000 metric tons of lithium carbonate from its planned U.S. project to LG Chem&#8217;s upcoming cathode plant in Tennessee, which is set to be the largest in the U.S.
LG Chem&#8217;s Tennessee cathode plant, which began construction in December 2023, is projected to produce 60,000 tons annually.
The facility&#8217;s strategic location ensures efficient customer deliveries and raw material imports.
The final investment decision will depend on establishing commercially viable regulatory frameworks.
ExxonMobil plans to produce Mobil Lithium using Direct Lithium Extraction (DLE) technology, leveraging its expertise in exploration, drilling, and chemical processing.
This method provides U.S. EV battery manufacturers with a domestic lithium supply option, which is expected to reduce environmental impact with about two-thirds lower carbon intensity compared to hard rock mining.
Shin Hak-cheol, CEO of LG Chem, said, &#8220;Building a lithium supply chain with ExxonMobil, one of the world&#8217;s largest energy companies, holds great significance.&#8221;
&#8220;We will continue to strengthen LG Chem&#8217;s competitiveness in the global supply chain for critical minerals.&#8221;
This month, Exxon Mobil reportedly planned to sell conventional Permian Basin assets for $1 billion,<a target="_blank" href="https://www.benzinga.com/news/asset-sales/24/11/41914956/exxon-mobil-sells-1-billion-in-permian-basin-assets-to-focus-on-shale-report" rel="noreferrer noopener"> producing ~26,000 BOE per day</a>.
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>).
Price Action: XOM shares are up 0.38% at $119.08 premarket at the last check Wednesday.
Photo via Midjourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42011906/exxon-mobil-set-to-cut-400-texas-jobs-after-pioneer-deal" target="_blank" rel="noreferrer noopener">Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026</a></li>
</ul>

Equities

Large Cap

DRLL

Exxon Mobil's Lithium Leap: 100,000 Metric Tons To Fuel LG Chem's US Plant

KULR

KULR Technology Group Announces The Development Of Its Carbon Fiber Designed Custom Cathodes In Small Modular Reactors For A Nuclear Fusion Company

KITT

Nauticus Robotics shares are trading higher after the company announced it entered into a strategic collaboration with SeaTrepid to integrate and test its ToolKITT software on remotely operated vehicles.

<a href="https://www.wolferesearch.com/eventsandconferences/" title="https://www.wolferesearch.com/eventsandconferences/">https://www.wolferesearch.com/eventsandconferences/</a>

Hess CEO Urges Trump Administration To Fill Up The Strategic Petroleum Reserve At A More Accelerated Rate

Barclays analyst Lauren Lieberman upgrades Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) from Equal-Weight to Overweight and raises the price target from $8 to $10.

Upgrades

Barclays Upgrades Newell Brands to Overweight, Raises Price Target to $10

SCOR

Comscore Awarded US Patent On Personifying Viewership Data

FLRT: No Longer An Attractive Entry Point (Rating Downgrade)

Pacer Pacific Asset Floating Rate High Income ETF declares monthly distribution of $0.2107

Pacer Pacific Asset Floating Rate High Income ETF declares monthly distribution of $0.4130

Pacer Pacific Asset Floating Rate High Income ETF declares monthly distribution of $0.299

Comments

Pacer Funds Pacer Pacific Asset Floating Rate High Income ETF

News

Latest news for Pacer Funds Pacer Pacific Asset Floating Rate High Income ETF (ARCA:FLRT)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga